Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Open
- Protocol: M23-699
- Drug: Upadacitinib
- Sponsor: Abbvie
- Description: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE
